Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Anti-EGFr Antibody in Metastatic Colorectal Cancer
NCT03017807Phase 1Completed
- Sponsor
- Kelun-Biotech
- Start
- Dec 2016
- Primary completion
- Jan 2018
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in colorectal cancer (CRC), sponsored by Kelun-Biotech. Primary endpoint: Number of patients with dose limiting toxicity at 4 weeks. Started Dec 2016; status: completed.
02
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03017807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03017807.